陰道炎治療藥物的全球市場規模、佔有率和成長分析：按類型、治療方法和分銷管道 - 行業預測（2024-2031）

2022年全球陰道炎治療藥物市場規模將為4.4億美元，預測期內（2024-2031年）複合年成長率為25.6%，從2023年的5.5億美元增至2031年的34.2億美元。

隨著越來越多的人患有陰道感染疾病，全球陰道感染疾病治療市場正在不斷擴大。市場正在轉向個人化和微創治療，重點是抗生素和益生菌的使用。新技術正在幫助開發診斷感染疾病的新治療方法和工具。市場上的領先公司花錢進行研究，並與其他公司合作創造更多產品。北美和歐洲佔據了大部分市場，因為它們擁有更好的醫療保健系統，人們對感染疾病有所了解。然而，隨著越來越多的人獲得醫療保健並了解這些感染疾病，快速發展的亞太國家預計將顯著成長。

目錄

執行摘要

• 市場概況
• 命運之輪

調查方法

• 資訊採購
• 次要/一級資訊來源
• 市場規模估算
• 市場假設與限制

母市場分析

• 市場概況
• 市場規模
• 市場動態
  • 促進因素
  • 機會
  • 抑制因素
  • 任務

主要市場考察

• 技術分析
• 價格分析
• 供應鏈分析
• 價值鏈分析
• 市場生態系統
• 智慧財產權分析
• 貿易分析
• Start-Ups分析
• 原料分析
• 創新矩陣
• 研發線產品分析
• 總體經濟指標
• 主要投資分析
• 關鍵成功因素
• 競爭程度

市場動態及展望

• 市場動態
  • 促進因素
  • 機會
  • 抑制因素
  • 任務
• 監管環境
• 波特的分析
• 對未來中斷的特殊考慮

全球陰道炎治療藥物市場：按類型

• 市場概況
• 細菌性陰道炎
• 酵母菌感染疾病
• 滴蟲病

全球陰道炎治療藥物市場：治療方法

• 市場概況
• 抗真菌藥物和抗生素藥物
• 局部霜
• 家庭治療

全球陰道炎治療藥物市場：依分銷管道分類

• 市場概況
• 藥局
• 電子商務
• 零售店

全球陰道炎治療藥物市場規模：按地區分類

• 市場概況
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲 (MEA)
  • 海灣合作理事會國家
  • 南非
  • 其他中東/非洲地區

競爭格局

• 前5名企業對比
• 主要企業市場定位（2021年）
• 主要市場參與者所採取的策略
• 關鍵成功策略
• 近期市集活動
• 主要企業市場佔有率（2021年）

主要企業簡介

• Pfizer Inc.（USA）
• Johnson & Johnson（USA）
• Novartis AG（Switzerland）
• GlaxoSmithKline plc（UK）
• Bayer AG（Germany）
• Sanofi（France）
• Merck & Co., Inc.（USA）
• Eli Lilly and Company（USA）
• AstraZeneca plc（UK/Sweden）
• AbbVie Inc.（USA）
• Gilead Sciences, Inc.（USA）
• Roche Holding AG（Switzerland）
• Bristol Myers Squibb（USA）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Astellas Pharma Inc.（Japan）
• Mylan NV（USA）
• Daiichi Sankyo Co., Ltd.（Japan）
• Takeda Pharmaceutical Company Limited（Japan）
• Boehringer Ingelheim（Germany）
• Sun Pharmaceutical Industries Ltd.（India）

Global Vaginitis Therapeutics market size was valued at USD 0.44 billion in 2022 and is poised to grow from USD 0.55 billion in 2023 to USD 3.42 billion by 2031, at a CAGR of 25.6% during the forecast period (2024-2031).

The worldwide market for treating vaginal infections is growing because more people are getting these infections. The market is moving towards treatments that are personalized and less invasive, with a focus on using antimicrobial drugs and probiotics. New technology is helping create new treatments and tools for diagnosing infections. Big companies in the market are spending money on research and working with others to make more products. North America and Europe have big parts of the market because they have good healthcare systems and people know about these infections. But countries in Asia-Pacific that are developing quickly could see big growth because more people are getting access to healthcare and learning about these infections.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Vaginitis Therapeutics Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Vaginitis Therapeutics Market Segmental Analysis

The global vaginitis therapeutics market is segmented on the basis of type, treatment, distribution channel, and region. By Type, the market is segmented into bacterial vaginosis, yeast infection, and trichomoniasis. By Treatment, the market is segmented into antifungal and antibiotic medications, topical creams, and home remedies. By Distribution channel, the market is segmented into pharmacies, e-commerce, and retail stores. By Region, the market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Drivers of the Global Vaginitis Therapeutics Market

Vaginitis, which includes different types of vaginal infections and inflammation, is a common problem for women all over the world. Many women have it, so there's a big need for treatments that work well. Things like not keeping clean, using some types of birth control, taking antibiotics, and changes in hormones can make vaginitis more likely to happen.

Restraints in the Global Vaginitis Therapeutics Market

Antibiotics are often used to treat bacterial vaginosis, a type of vaginitis. But using antibiotics too much or not in the right way has made some bacteria become resistant to them. This means antibiotics might not work as well to treat bacterial vaginosis, and it can be harder to manage the infection.

Market Trends of the Global Vaginitis Therapeutics Market

A big trend in treating vaginal infections is that more women are learning about their reproductive health. They want to know more about how to find out if they have an infection, how to treat it, and how to stop it from happening again. Because of this, more women might see a doctor early on if they think they have an infection, which means there's a bigger need for treatments that work well.

Table of Contents

Executive Summary

• Market Overview
• Wheel of Fortune

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Parent Market Analysis

• Market Overview
• Market Size
• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges

Key Market Insights

• Technology Analysis
• Pricing Analysis
• Supply Chain Analysis
• Value Chain Analysis
• Ecosystem of the Market
• IP Analysis
• Trade Analysis
• Startup Analysis
• Raw Material Analysis
• Innovation Matrix
• Pipeline Product Analysis
• Macroeconomic Indicators
• Top Investment Analysis
• Key Success Factor
• Degree of Competition

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Regulatory Landscape
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers
• Skyquest Special Insights on Future Disruptions
  • Political Impact
  • Economic Impact
  • Social Impact
  • Technical Impact
  • Environmental Impact
  • Legal Impact

Global Vaginitis Therapeutics Market by Type

• Market Overview
• Bacterial vaginosis
• yeast infection
• and trichomoniasis

Global Vaginitis Therapeutics Market by Treatment

• Market Overview
• Antifungal and antibiotic medications
• topical creams
• and home remedies

Global Vaginitis Therapeutics Market by Distribution channel

• Market Overview
• Pharmacies
• e-commerce
• and retail stores

Global Vaginitis Therapeutics Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2021
• Strategies Adopted by Key Market Players
• Top Winning Strategies
  • By Development
  • By Company
  • By Year
• Recent Activities in the Market
• Key Companies Market Share (%), 2021

Key Company Profiles

• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc (UK/Sweden)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan N.V. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Daiichi Sankyo Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments